1 completed, 1 unknown. 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Markus Joerger: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tinostamustine and Nivolumab in Advanced Melanoma Tinostamustine - Malignant Melanoma | Phase 1 | Unknown | Markus Joerger | 21 | 2019-03-07 | 2019-04-08 |
| Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Sunitinib, Erlotinib, Midazolam - Non Small-cell Lung Cancer, Renal-cell Cancer | Phase 4 | Completed | Markus Joerger | 54 | 2012-01-01 | 2016-02-02 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Gastrointestinal Stromal Tumors (1) · Lung Neoplasms (1) · Melanoma (1)
Caffeine (1) · Erlotinib Hydrochloride (1) · Midazolam (1) · Nivolumab (1) · Sunitinib (1) · tinostamustine (1)
Switzerland (2)